Loading clinical trials...
Loading clinical trials...
Epidiolex® For The Treatment Of Anxiety Comorbidity in Refractory Pediatric Epilepsy
Conditions
Interventions
Cannabidiol 100 MG/ML
Locations
1
United States
Kennedy Krieger Institute
Baltimore, Maryland, United States
Start Date
April 5, 2022
Primary Completion Date
March 17, 2025
Completion Date
May 5, 2025
Last Updated
July 2, 2025
NCT02531880
NCT07073963
NCT05883540
NCT07315516
NCT06066983
NCT06968026
Lead Sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions